Chronic metabolic acidosis results in metabolic bone disease, calcium nephrolithiasis, and growth retardation. The pathogenesis of each of these sequelae is poorly understood in humans. We therefore investigated the effects ofchronic extrarenal metabolic acidosis on the regulation of 1,25-(OH)2D, parathyroid hormone, calcium, and phosphate metabolism in normal humans. Chronic extrarenal metabolic acidosis was induced by administering two different doses of NH4CI 12.1 (low dose) and 
Introduction
Chronic metabolic acidosis results in metabolic bone disease, calcium nephrolithiasis, and growth retardation. The pathogenesis of each of these sequelae is poorly understood in humans. We therefore investigated the effects ofchronic extrarenal metabolic acidosis on the regulation of 1,25-(OH)2D, parathyroid hormone, calcium, and phosphate metabolism in normal humans. Chronic extrarenal metabolic acidosis was induced by administering two different doses of NH4CI 12.1 (low dose) and 4.2 (high dose) mmol/kg body wt per d, respectively] to four male volunteers each during metabolic balance conditions. Plasma IHCO3I decreased by 4.5±0.4 mmol/liter in the low dose and by 9.1±0.3 mmol/liter (P < 0.001 ) in the high dose group. Metabolic acidosis induced renal hypophosphatemia, which strongly correlated with the severity of acidosis (Plasma 1P041 on plasma [HCO-1; r = 0.721, P < 0.001). Both metabolic clearance and production rates of 1,25-(OH)2D increased in both groups. In the high dose group, the percentage increase in production rate was much greater than the percentage increase in metabolic clearance rate, resulting in a significantly increased serum 1,25-(OH)2D concentration. A strong inverse correlation was observed for serum 1,25-(OH)2D concentration on both plasma IP041 (r = -0.711, P < 0.001 ) and plasma IHCO31 (r = -0.725, P < 0.001). Plasma ionized calcium concentration did not change in either group whereas intact serum parathyroid hormone concentration decreased significantly in the high dose group. In conclusion, metabolic acidosis results in graded increases in serum 1,25-(OH)2D concentration by stimulating its production rate in humans. The increased production rate is explained by acidosis-induced hypophosphatemia/cellular phosphate depletion resulting at least in part from decreased renal tubular phosphate reabsorption. The decreased serum intact parathyroid hormone levels in more severe acidosis may be the consequence of hypophosphatemia and/or increased serum 1,25-(OH)2D concentrations. (J. Clin. Invest. 1992 . 90:2456-2463.) Key words: metabolic acidosis. 1,25-(OH)2D-parathyroid hormone * metabolic clearance rate * production rate * hypophosphatemia * NH4Cl feeding Receivedfor publication 25 November 1992 and in revisedform 12 February 1992.
Chronic metabolic acidosis occurs as the result ofan increase in the systemic acid load (by either extrarenal loss of base or increase in acid production) or as the result of congenital or acquired defects in renal acid excretion (e.g., renal tubular or uremic acidosis). Metabolic acidosis profoundly affects calcium and phosphate metabolism resulting in calcium losses from bone ( 1 ) in association with hypercalciuria. Important clinical sequelae are a metabolic bone disease resembling osteomalacia (2) (3) (4) (5) (6) (7) (8) and calcium nephrolithiasis (9) .
Reduced serum concentrations of the active metabolite of vitamin D, 1,25-(OH)2D, have been implicated in mediating the acidosis-induced metabolic bone disease (8, 10 , I 1). The low 1,25-(OH )2D serum concentrations have been pathogenetically attributed to diminished renal l-alpha-hydroxylase activity (12) (13) (14) , although not all studies have been consistent with an impaired conversion of 25-(OH)D to 1,25-(OH)2D ( 15) .
However, the results of measurements of serum 1,25-(OH)2D concentration during experimentally induced metabolic acidosis have not been consistent: reported values have ranged from increased to unchanged to decreased mean concentrations (15) (16) (17) (18) (19) . These inconsistencies may have been due in part to the experimental difficulties in controlling acidosisinduced alterations in the plasma concentrations of known modulators of 1,25-(OH)2D production: phosphate (20) (21) (22) , calcium (23) , and parathyroid hormone (23, 24) . Moreover 
Methods
The protocol was designed to measure the effects ofchronic NH4Cl-induced metabolic acidosis on calcium, phosphate, and 1,25-(OH)2D metabolism as well as serum parathyroid hormone levels in normal humans. These parameters were determined in eight normal male subjects during metabolic balance studies. None were smokers or were taking any drugs before and during the study. They ate a constant metabolic diet for 2 5 d before the study (prefeeding phase) and during the two study periods (control and acidosis). The Analytical procedures. All measurements were performed in duplicate. Analysis of plasma and urine electrolyte and acid-base composition were performed as described previously (27 Results are reported as mean±SEM unless stated otherwise. Statistical significance was determined by simple and multiple linear regression, covariance analysis, and Student's t test for paired or unpaired data, as appropriate.
Results
Both groups of subjects tolerated the protocol well. The mean steady state plasma acid-base and electrolyte composition, albumin concentration, alkaline phosphatase activity, creatinine clearance rate, and body weight are shown in Table I . The steady state values for urinary acid-base and electrolyte excretion are given in Table II . The administration of NH4Cl decreased the mean±SEM steady state plasma bicarbonate concentration by 4.5±0.3 mmol/liter in the group receiving 2.1 mmol (low dose group) and by 9.1±0.4 mmol/liter in the group receiving 4.2 mmol NH4Cl/kg body wt per d (high dose group, P < 0.001 ). A similar dose-response to the two levels of oral acid load was observed in the rate of net acid excretion (NAE , Table II) : NAE increased to 142.5±7.4 mmol/24 h in the low dose group, whereas subjects in the high dose group (ingesting twice the amount of NH4Cl as the low dose group) excreted approximately twofold more acid (270.2±9.6 mmol/ 24 h, P < 0.001 ). All subjects in both groups lost weight significantly. NH4C1 feeding decreased plasma potassium concentration and albumin concentration significantly only in the high dose group.
The effects of metabolic acidosis on calcium, phosphate, 1,25-(OH)2D metabolism, and parathyroid hormone are illustrated in Table III and Figs. 1 and 2, which depict the mean daily values for the low and high dose groups. Steady state plasma-ionized calcium concentration did not change significantly in response to metabolic acidosis in either group, despite a large and significant increase in the total and fractional urinary excretions of calcium. However, as illustrated in Fig. 2 , there was a transient small increase in calcium concentration during the adaptation to metabolic acidosis. This transient increase was observed only in the high dose group. Plasma phosphate concentration decreased in a dose-dependent fashion in response to metabolic acidosis: whereas hypophosphatemia was mild and not statistically significant in the low dose group, the decrement in plasma phosphate concentration of -0.26±0.05 mmol/liter in the high dose group was significant (P < 0.001 ). Acidosis-induced hypophosphatemia in the high dose group averaged 0.87±0.04 mmol/liter and was significantly more severe than that observed in the low dose group Metabolic Acidosis Increases Serum 1,25-(OH)2D Concentration Fig. 3 A, and the relationships between each of these parameters and serum 1,25-(OH)2D concentration are depicted in Fig. 3 (32) . Thus, the possibility might be considered that renal potassium wasting induced by chronic mineral acidosis could induce both hypophosphatemia and secondarily increased serum 1,25-(OH)2D concentration. However, no significant correlation was obtained for the relation of steady state plasma phosphate on plasma potassium concentration (r = 0.475), although a significant inverse correlation does obtain for serum 1,25-(OH)2D on plasma potassium concentration (r = 0.542, P < 0.05). This correlation is, however, substantially weaker than that for serum 1 ,25-(OH)2D on plasma phosphate concentration (Fig.  3B) .
To evaluate a possible influence of metabolic acidosis on the diurnal variation of plasma ionized calcium, plasma phosphate, serum 1,25-(OH)2D, and serum intact parathyroid hormone concentrations, these values were determined at 1800 as well as at 0700 during steady state days during both the control and experimental periods. As illustrated in Fig. 4 (Fig. 3 A) and an equally strong inverse correlation of serum 1,25-(OH)2D concentration with plasma phosphate concentration ( Fig. 3 B) ; and (e) intact parathyroid hormone decreased significantly in response to metabolic acidosis in the high dose group (Table  III, Fig. 2 ). Our finding of an enhanced 1,25-(OH)2D MCR represents the first report ofthis measurement in acidosis and is consistent with recent results ofstudies demonstrating enhanced degradation of labeled 1,25-(OH)2D in vitamin D-deficient chicks with NH4Cl-induced metabolic acidosis (33) . The mechanism of the apparent acidosis-induced enhancement of MCR has not been investigated in this study. However, it is interesting to note that the MCR ofanother steroid hormone, aldosterone, is enhanced in response to dietary potassium depletion (34) . The present observations indicate that the observed increase in the MCR can be overridden by an even greater increase in the PR of 1,25-(OH)2D. We are unaware of other metabolic disturbances that simultaneously increase both the PR and MCR of any hormone.
Dietary-induced decreases and increases in plasma phosphate concentration have been shown to increase and decrease serum 1,25-(OH)2D concentration, respectively, in humans by altering its PR (20) (21) (22) . Hypophosphatemia, hypocalcemia, and parathyroid hormone excess are the best-known stimulators of 1 ,25-(OH)2D PR. When all steady state values of this study were analyzed (Fig. 3 B) , a significant inverse correlation was demonstrable for the relation of serum 1,25-(OH)2D as a function of plasma phosphate concentration. This observation coupled with the findings that plasma ionized calcium concentration did not change and that parathyroid hormone serum concentrations were unchanged (low dose group) or even decreased (high dose group) indicate a dominant role for hypophosphatemia and/or cellular phosphate depletion in acidosisinduced stimulation of 1,25-(OH)2D production. 2 The present studies also demonstrate a strikingly strong direct correlation of plasma phosphate with plasma bicarbonate concentration (Fig. 3 A) , consistent with our previous observations in another group ofhumans (25) . However, other studies in humans have not reported consistent acidosis-induced changes in plasma phosphate concentration, which was found to be either unchanged (35) (36) (37) or decreased (38, 39) . Similar inconsistencies are reported in previous animal studies (rat, dog, and chick; references 12, 16-18, 33, 40-44) . However, the results from the subjects in the low dose group (no significant decrease in plasma phosphate concentration) and the observation from other studies that the greatest reductions in plasma 2. Prevention ofNH4Cl-induced hypophosphatemiaby either administering large oral doses of neutral phosphate or by pharmacologically increasing renal tubular phosphate reabsorption (e.g., by diphosphonates) might be considered to yield more direct evidence for the hypothesis that hypophosphatemia and/or cellular phosphate depletion is the sole determinant of elevated serum 1,25-(OH)2D concentration during metabolic acidosis. However, even massive increases in oral phosphate intake (95.8 mmol/d) have been insufficient to increase fasting plasma phosphate concentration in humans with metabolic acidosis (41) . Moreover, this approach would not be useful even if normophosphatemia was achievable inasmuch as phosphate loading of this magnitude would almost certainly result in severe hyperparathyroidism. Diphosphonates, on the other hand, have been shown to exert independent effects on intestinal calcium transport, vitamin D, and bone metabolism (61) . Thus, currently available diphosphonates are of insufficient specificity to further address this question. Chronic NH4C1 administration has been reported previously in humans to increase renal phosphate clearance (37) , which accounts for most of the negative phosphate balance during prolonged acidosis (36) . The present studies demonstrating increased fractional excretion of phosphate despite steady state hypophosphatemia are consistent with an acidosisinduced renal phosphate leak. The cellular mechanism(s) of decreased renal tubular phosphate reabsorption in response to acidosis is (are) currently unknown.
Chronic dietary potassium loading has been reported recently to result in chronic renal hyperphosphatemia and decreased 1,25-(OH )2D serum concentration (32) . We therefore considered the possibility that the renal potassium wasting of mineral acidosis might be responsible for both hypophosphatemia and secondarily increased serum 1,25-(OH)2D concentration. However, no significant correlation was obtained for the relation of steady state values of plasma phosphate on potassium concentration (r = 0.475, n = 16). A statistically significant inverse correlation does obtain for serum 1,25-(OH)2D on plasma potassium concentration (r = 0.542, n = 16), but this correlation is substantially less significant than the correlation for serum 1,25-(OH)2D on plasma phosphate concentration (r = 0.71 1, n = 16; Fig. 3 B) . These results suggest that other factors in addition to potassium homeostasis determine both plasma phosphate and serum 1,25-(OH)2D concentrations in chronic mineral acidosis. The possibility ofan ancillary direct phosphate-independent effect of potassium metabolism on 1,25-(OH)2D production in metabolic acidosis can not be excluded by the present results. However, there are no reported effects of potassium metabolism on 1,25-(OH)2D metabolism.
The present results in acidotic human subjects might appear to disagree with the repeated finding in rats that chronic mineral acidosis results in significant decreases in serum 1,25-(OH)2D concentration (17) (18) (19) . However, in each of the protocols in rats, chronic metabolic acidosis was associated with increased plasma ionized calcium concentration (17) (18) (19) PR and serum concentration of 1,25-(OH)2D (23, 45, 46) . Only when hypophosphatemia/cellular phosphate depletion is severe has acidosis-induced hypercalcemia failed to suppress a hypophosphatemia-induced increase in serum 1,25-(OH)2D concentration (40) . In the present studies, hypercalcemia was not observed and, more importantly, a significant correlation of serum 1,25-(OH)2D with plasma ionized calcium concentration (r = 0. 17, linear slope = +29. 1 pg./ mL per mmol/liter) did not obtain. The finding of a significant decrease (high dose group) in serum parathyroid hormone concentration in response to chronic metabolic acidosis is in agreement with a previous report in humans (35) . However, other reports have found either increased (47, 48) or unchanged ( 15, 39) values. Although it is possible that the older parathyroid hormone assays were responsible for the failure to detect the small decreases in parathyroid hormone concentration detected herein, other explanations also need to be considered. Since the dose of NH4C1 administered to the subjects of the present study (4.2 mmol/kg per 24 h, high dose group) was substantially greater than that employed previously, and since this large dose of NH4C1 resulted in a greater decrement in steady state phosphate concentration, it is possible that hypophosphatemia-induced hypoparathyroidism contributed to the observed decrease in intact parathyroid hormone concentration in this group (49, 50) . The sustained elevation of serum 1,25-(OH)2D concentration per se may also have contributed to suppression ofparathyroid hormone secretion and serum concentration (51 ) .
The present experiments provide an opportunity to reinterpret previous observations on the role ofparathyroid hormone in metabolic acidosis. On the basis of measurements of immunoreactive NH2-terminal parathyroid hormone in chronic NH4Cl-induced acidosis in humans (47, 48) and acute NH4Cl-induced acidosis in rats (52), it was suggested that both acute and chronic acidosis elicits a state ofhyperparathyroidism that, at least in rats (52), is critical to the full expression ofthe renal acid excretory response. Our findings herein using the modem two-site intact parathyroid hormone assay provide strong evidence that elevated levels of parathyroid hormone (54, 55) .
The results ofthe present studies help to integrate a number of interesting issues regarding the complex and interrelated pathophysiology of metabolic acidosis, hypophosphatemia, and metabolic bone disease. First, 1,25-(OH)2D is a potent stimulus to bone resorption (56, 57) . Second, mild phosphate depletion has been shown to enhance bone resorption and to decrease bone mineralization in rats (58) . Moreover, the severity of hypophosphatemia-induced enhanced bone resorption was greatly attenuated by experimental vitamin D deficiency. Third, rats with chronic mineral acidosis and associated hypophosphatemia exhibit increased bone resorption as well as decreased bone formation (59, 60) . Fourth, hypophosphatemia is often present during chronic acidosis of either renal tubular or extrarenal etiology (59, 60) and the reversal of skeletal lesions by alkali treatment alone is associated with a markedly positive phosphate balance (3, 5 
